GlassScriptPhysician profile
Muhammad A Gul
NPI 1144438193
$1,025.98
in general payments reported to CMS, 2019-2025
21 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $115 · 2023: $43.20 · 2024: $158 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $154.53 | 2019-2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $138.03 | 2019-2020 | |
| Lilly USA, LLC | $127.95 | 2019-2024 | Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $74.88 | 2019-2020 | |
| Pfizer INC. | $62.22 | 2019-2025 | |
| Novo Nordisk INC | $54.15 | 2019-2025 | Ozempic, Rybelsus |
| Alkermes, INC. | $42.63 | 2024-2025 | Vivitrol |
| Baxter Healthcare | $41.62 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $39.81 | 2019-2020 | |
| Allergan, INC. | $35.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $32.52 | 2019 | |
| Abbvie INC. | $30.60 | 2025 | |
| Verona Pharma, INC. | $28.80 | 2025 | Ohtuvayre |
| Abbott Laboratories | $27.29 | 2024 | Freestyle Libre 3 |
| Braeburn INC. | $27.15 | 2023 | Brixadi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.66 | 2019 | |
| Neuronetics, INC. | $19.61 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.53 | 2024 | Jardiance |
| Seqirus USA INC | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Gul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.